[A case of "chronic" leukemic reticuloendotheliosis with excellent response to chemotherapy (author's transl)]. 1975

H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008206 Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. Lymphatism,Status Lymphaticus,Disease, Lymphatic,Diseases, Lymphatic,Lymphatic Disease
D008297 Male Males
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
January 1981, Przeglad lekarski,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
November 1975, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
May 1976, Archives of internal medicine,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
May 1976, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
September 1976, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
August 1982, Cancer,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
October 1979, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
October 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
June 1952, Minerva medica,
H Yoshikawa, and H Takeyama, and J Ishiguro, and K Yamada, and M Suenaga
May 1963, Archives of ophthalmology (Chicago, Ill. : 1960),
Copied contents to your clipboard!